Okyo Pharma (NASDAQ:OKYO) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of OK-101.
OK-101 is the company’s drug candidate for the treatment of dry eye disease (DED). Today’s news includes the clinical trial being posted on the ClinicalTrials.gov public website. This comes as the company prepares to launch this phase of its study.
According to Okyo Pharma, it’s already working to activate clinical sites for the study. The company is also having OK-101 prepared for shipment to these locations. This has it expecting the first patient visit in the second quarter of 2023.
With the progress that Okyo Pharma is making, some investors are likely wondering when they’ll see results from this trial. If all goes well, the company intends to have the data ready to go in Q4 2023.
Gary Jacob, CEO of Okyo Pharma, said the following about the news:
“We are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs.”
OKYO Stock Movement on Thursday
Investors are piling into OKYO stock following today’s clinical trial update. This has some 5 million shares changing hands as of this writing. That’s a massive surge compared to the company’s daily average trading volume of about 566,000 shares.
OKYO stock is up 13.4% as of Thursday morning.
There’s even more stock market news worth knowing about below!
We’ve got all of the hottest stock news traders will want to read about on Thursday! A few examples include why shares of Baidu (NASDAQ:BIDU), Credit Suisse (NYSE:CS) and Western Alliance Bancorp (NYSE:WAL) stock are moving today. You can find all that news at the following links!
More Thursday Stock Market News
- Baidu (BIDU) Stock Sees Volatility as AI Chatbot Ernie Disappoints
- CS Stock Alert: Can $54 Billion Save Credit Suisse?
- WAL Stock Alert: Fitch Places Western Alliance on Watch
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.